Antibodies to IP-10 for treating bone diseases with bone destruction
US8178100B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2007 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | May 13, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating a disease or disorder associated with the expression of RANKL (receptor activator of NF-κB ligand), (ii) a method for inhibiting the expression of RANKL and (iii) a method for screening an antibody drug candidate to inhibit the expression of RANKL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.